A Phase 1/2 interventional study of BTZ-043 and Rifafour e-275® in Pulmonary Tuberculoses and Other Specified Pulmonary Tuberculosis, sponsored by Michael Hoelscher. Completed at 2 sites in South Africa. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-08-31.
Sponsored by Michael Hoelscher · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 78 studies in Tuberculosis, Pulmonary with a site in South Africa — 10 open to participants now, 13 under way, 3 of them phase 3. Tuberculosis, Pulmonary · South Africa.
Among the 78 studies in Tuberculosis, Pulmonary with a site in South Africa, this one is the 50th largest by enrollment of the 67 interventional ones that give a count, is one of 4 that started in 2019, is one of 2 in phase 1/2, and was the 37th registered.
320 studies on the registry are indexed under Tuberculosis, Pulmonary; 72 are open to participants now.
Browse Tuberculosis, Pulmonary studies →10 of the 78 studies in Tuberculosis, Pulmonary with a site in South Africa are open now. Recruiting first, the newest first:
North-West University, South Africa · Sites in South Africa
Ages 18–45
Global Alliance for TB Drug Development · Sites in South Africa, Tanzania
Ages 18–65
Gates Medical Research Institute · Sites in South Africa
Ages 18–65
Thirty Respiratory Limited · Sites in South Africa
Ages 18–65
TASK Applied Science · Sites in South Africa
Ages 18–65
A study can be open while its sites in South Africa have not opened yet or have stopped. Only those recruiting at a site in South Africa →
Of the 47 Tuberculosis, Pulmonary studies recruiting now, 22 (47%) set no upper age limit and 21 (45%) stop at 75 or younger; 12 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
78 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 57 · Phase 3 11
First in 2003; this study’s year is marked. 4 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 78 is below the median of 147 across 228 interventional studies indexed under Tuberculosis, Pulmonary.
Median enrollment 122 across the 67 interventional studies, 900 across the 11 observational. Of the 57 that completed or were terminated, 31 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 78 have an industry lead sponsor. The 10 most frequent:
Michael Hoelscher is the lead sponsor of 19 studies on the registry; 4 are open to participants now.
Michael Hoelscher has 9 studies filed under Tuberculosis, Pulmonary — fewer than ten, so there is no comparison to draw.
6 of the studies in Tuberculosis, Pulmonary with a site in South Africa that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05766267Phase 3Centers for Disease Control and PreventionShort-course Regimens for the Treatment of Pulmonary Tuberculosis | 2026-12-31 |
| NCT06253715Phase 3Johns Hopkins UniversityShortened Regimen for Drug-susceptible TB in Children | 2027-09-30 |
| NCT06114628University College, LondonPlatform Assessing Regimens and Durations In a Global Multisite Consortium for TB | 2027-02-24 |
| NCT07672405Global Alliance for TB Drug DevelopmentSorfequiline-based Regimens in Adults With Newly Diagnosed Drug-sensitive Pulmonary TB | 2027-05-28 |
| NCT05807399Michael HoelscherPanACEA - STEP2C -01 | 2027-10-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 78 studies in Tuberculosis, Pulmonary with a site in South Africa, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a prospective, open label, two-centre, randomized, controlled, two-stage, phase Ib/IIa study to evaluate the safety, tolerability, PK, drug-drug interaction and bactericidal activity of BTZ-043 administered orally once daily over 14 days to participants with newly diagnosed, uncomplicated, smear-positive, drug-susceptible pulmonary tuberculosis.
The primary objective is to assess the safety and tolerability of BTZ-043 given over 14 days by evaluation of adverse events during treatment and follow-up period in patients with newly diagnosed, uncomplicated, smear-positive, drug-susceptible pulmonary tuberculosis.
This is a prospective, open label, two-centre, randomized, controlled, two-stage, phase Ib/IIa study to evaluate the safety, tolerability, PK, drug-drug interaction and bactericidal activity of BTZ-043 administered orally once daily over 14 days to participants with newly diagnosed, uncomplicated, smear-positive, drug-susceptible pulmonary tuberculosis:
Stage 1 is an escalating dose design in up to eight cohorts receiving different doses of BTZ-043 to define a safe dose corridor for BTZ-043. The focus of this stage is on adverse events, PK and a food-effect PK-evaluation .
Stage 2 is a parallel group comparison of 4 arms receiving different treatment regimens: three arms to receive BTZ-043 in different doses within the safe corridor defined in stage 1, compared to one arm receiving Rifampicin, Isoniazid, Pyrazinamide, and Ethambutol as a control. This stage is focusing on adverse effects, early bactericidal activity (EBA), PK and an evaluation of PK drug-drug interaction potential.
A total of up to 77 male and female patients, aged ≥ 18 - 64 years, with newly diagnosed, smear positive, drug sensitive pulmonary tuberculosis will be enrolled.
Allocation of patients will be carried out in two stages:
Stage 1: for each cohort 3 patients will be enrolled, treated and followed-up accordingly, starting with cohort 1. In a Trial Steering Committee (TSC) meeting, decision will be made on the dose in the next cohort.
Dose escalation steps to be followed, if no safety concerns arise:
Patients receiving the investigational drug in cohorts 1 - 8 will take BTZ-043 in fasting state for 13 days and after a pre-defined high-fat, high-caloric meal on day 14.
After all patients of a current cohort have completed at least 7 days of dosing, the TSC, composed of the national principal investigator (PI), the trial statistician, the sponsor representative and two independent scientists, will review safety data, including clinical, lab and electrocardiography (ECG) data, to assess whether dose limiting toxicity of BTZ-043, as defined below, has been observed in any participant. Depending on the outcome, the TSC will then decide on dose escalation, or on enrolling more participants to the same or a lower dose in the following cohort, according to dose escalation and stopping rules.
After the end of stage 1, the TSC will decide which of the BTZ-043 doses, which are deemed to not exceed the acceptable toxicity level, are to be moved to stage 2.
Stage 2: after the highest possible dose of the investigational drug, that has proven to be safe within the 1st stage, is identified, all remaining patients will be recruited and randomised to receive one of three different doses of BTZ-043 or to control treatment with Rifafour e-275® at a ratio of 3:3:3:2 favouring the experimental treatment.
Stage 2 is focusing on adverse effects, early bactericidal activity (EBA), PK and an evaluation of PK drug-drug interaction potential.
Allocation of patients:
Participants will take in BTZ-043 in either fasted or fed state, depending on which state has shown to lead to higher exposure during the 1st stage.
Additional measurements in the 2nd stage in BTZ-arms 1 to 3 only:
After the course of study drugs is completed (on day 14), all patients (in stage 1 and stage 2) will be referred to a government clinic to complete their course of tuberculosis (TB) according to national standards for a total of 6 months of first-line therapy.
General inclusion criteria:
Participants are either unable to conceive/father children AND/OR they will be using two effective methods of , including methods used by the patient's sexual partner(s). At least one to be a barrier method.
Disease-specific inclusion criteria:
General exclusion criteria:
The patient is pregnant or breast-feeding.
Disease-specific exclusion criteria:
The patient has a history of or current evidence of cardiovascular metabolic, gastrointestinal, neurological, psychiatric or endocrine diseases, or any other condition, that will influence treatment response, study adherence or survival in the judgement of the investigator, especially:
Laboratory exclusion criteria at screening:
serum potassium below the lower level of normal (LLN) for the laboratory
-specific exclusion criteria:
any other changes in the ECG that are clinically relevant as per discretion of the investigator
Restricted medication:
Requires medication as included in the following drug classes within 2 weeks prior to the first dose of study treatment:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive 1 tablet of BTZ-043 orally once daily, containing 250mg BTZ-043 from Day 1 through to Day 14
Drug: BTZ-043
Patients will receive 2 tablets of BTZ-043 orally once daily, each containing 250mg BTZ-043 (500 mg in total) from Day 1 through to Day 14
Drug: BTZ-043
Patients will receive 3 tablets of BTZ-043 orally once daily, each containing 250mg BTZ-043 (750 mg in total) from Day 1 through to Day 14
Drug: BTZ-043
Patients will receive 4 tablets of BTZ-043 orally once daily, each containing 250mg BTZ-043 (1000 mg in total) from Day 1 through to Day 14
Drug: BTZ-043
Patients will receive 5 tablets of BTZ-043 orally once daily, each containing 250mg BTZ-043 (1250 mg in total) from Day 1 through to Day 14
Drug: BTZ-043
Patients will receive 6 tablets of BTZ-043 orally once daily, each containing 250mg BTZ-043 (1500 mg in total) from Day 1 through to Day 14
Drug: BTZ-043
Patients will receive 7 tablets of BTZ-043 orally once daily, each containing 250mg BTZ-043 (1750 mg in total) from Day 1 through to Day 14
Drug: BTZ-043
Patients will receive 8 tablets of BTZ-043 orally once daily, each containing 250mg BTZ-043 (2000 total) from Day 1 through to Day 14
Drug: BTZ-043
Patients will receive a higher dose of BTZ-043, that has proven to be safe in stage 1 orally once daily from Day 1 through to Day 14. The dose of BTZ-043 will be determined after review of safety data from stage 1.
Drug: BTZ-043 · Drug: Probe Drug Cocktail · Drug: Dolutegravir 50mg Tab
Patients will receive a medium dose of BTZ-043, that has proven to be safe in stage 1 orally once daily from Day 1 through to Day 14. The dose of BTZ-043 will be determined after review of safety data from stage 1.
Drug: BTZ-043 · Drug: Probe Drug Cocktail · Drug: Dolutegravir 50mg Tab
Patients will receive a lower dose of BTZ-043, that has proven to be safe in stage 1 orally once daily from Day 1 through to Day 14. The dose of BTZ-043 will be determined after review of safety data from stage 1.
Drug: BTZ-043 · Drug: Probe Drug Cocktail · Drug: Dolutegravir 50mg Tab
Patients will receive a standard dose of Rifafour e-275® orally once daily according to body weight from Day 1 through to Day 14. Each tablet of Rifafour e-275® contains 150mg rifampicin, 75mg isoniazid, 400mg pyrazinamide and 275mg ethambutol. The daily doses will be given to fasting patients, in accordance with South African Guidelines for treatment of TB. The total number of tablets will be based on the body weight at screening: * participants weighing 38 - 54 kg: 3 tablets * participants weighing 55 - 70 kg: 4 tablets * participants weighing \>70 kg: 5 tablets
Drug: Rifafour e-275®
BTZ-043 (250mg per tablet)
Drug pages: IsoniazidStudies of IsoniazidIsoniazid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · RifampinStudies of RifampinRifampin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · PyrazinamideStudies of PyrazinamidePyrazinamide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · EthambutolStudies of EthambutolEthambutol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Rifafour e-275® (150mg rifampicin, 75mg isoniazid, 400mg pyrazinamide, 275 mg ethambutol per tablet)
Also known as: Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE)
A probe drug cocktail will be given to randomly selected patients after inclusion on Day 1 and on Day 14 once orally. The probe drug cocktail consists of * Caffeine: 1 tablet à 150mg * Tolbutamide: 1/4 tablet à 500mg * Dextromethorphan: 10 ml syrup à 15mg/5ml * Midazolam:2 ml solution à 5mg/5ml * Digoxin: 2 tablets à 0.25mg
1 tablet à 50mg Dolutegravir will be given to randomly selected patients after inclusion on Day 1 and on Day 14 once orally.
Also known as: Tivicay®
Safety and Tolerability of BTZ-043
Safety and tolerability of BTZ-043 was assessed by evaluation of Adverse Events (AEs) during treatment- and follow-up phase (Clinical observations, Vital signs, Serum chemistry, hematology and coagulation parameters with baseline measurements. Electrocardiography (ECG), including heart rate, PR interval, QRS, QT interval, QTcF; change of QTcF from baseline; morphological abnormalities).
Time frame: Day 1 to Day 22
Bactericidal Activity Endpoint - MGIT Time to Positivity (log10 (h))
Liquid culture is inoculated with overnight sputum of the participants. Upon growth of Mycobacteria, the color of the medium is changing due to changes in pH. This is measured photometric and the time of the change in color is recorded. The more bactera are inoculated, the quicker the change ind color and the time to positivity. Overnight sputum is collected on Day -1, Day 0, Day 2, Day 3, Day 4, Day 6, Day 8, Day 11 and Day 14 to be able to follow the decrease in bacterial load over time.
Time frame: Day -1 to Day 14. Change from Day -1 to Day 2, Day 2 - Day 14 and Day -1 to Day 14 have been assessed.
Bactericidal Activity Endpoint - CFU
Overnight sputum was plated on solid medium. Decrease in log 10 CFU (No. of colony forming untis) over time was assessed. Overnight sputum is collected on Day -1, Day 0, Day 2, Day 3, Day 4, Day 6, Day 8, Day 11 and Day 14 to be able to follow the decrease in bacterial load over time.
Time frame: Day -1 to Day 14. Change from Day -1 to Day 2, Day 2 - Day 14 and Day -1 to Day 14 have been assessed.
Patients were recruited from the local TB clinics, informed and consented. With the signature of the ICF, the participants were subject to screening (up to 8 days). If participant proved to be eligible, participant was allocated (stage1) or randomized (stage 2) to treatment. One participant in stage 2 was randomized but experienced an SAE before the first administration of study medication, was withdrawn from the study and replaced. This led to enrolment of 78 p. but ony 77 were started on IMP
| Milestone | Stage 1 - Cohort 1 (BTZ 250) | Stage 1 - Cohort 2 (BTZ 500) | Stage 1 - Cohort 3 (BTZ 750) | Stage 1 - Cohort 4 (BTZ 1000) | Stage 1 - Cohort 5 (BTZ 1250) | Stage 1 - Cohort 6 (BTZ 1500) | Stage 1 - Cohort 7 (BTZ 1750) | Stage 1 - Cohort 8 (BTZ 2000) | Stage 2 - Arm 1 (BTZ High) | Stage 2 - Arm 2 (BTZ Medium) | Stage 2 - Arm 3 (BTZ Low) | Stage 2 - Arm 4 (Control) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 3 | 3 | 3 | 3 | 3 | 6 | 0 | 16 | 13 | 15 | 9 |
| Completed | 3 | 3 | 3 | 1 | 3 | 3 | 3 | 0 | 15 | 11 | 13 | 7 |
| Not completed | 0 | 0 | 0 | 2 | 0 | 0 | 3 | 0 | 1 | 2 | 2 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 2 | 0 | 0 | 3 | 0 | 1 | 2 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Covid19 infection | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
Safety and tolerability of BTZ-043 was assessed by evaluation of Adverse Events (AEs) during treatment- and follow-up phase (Clinical observations, Vital signs, Serum chemistry, hematology and coagulation parameters with baseline measurements. Electrocardiography (ECG), including heart rate, PR interval, QRS, QT interval, QTcF; change of QTcF from baseline; morphological abnormalities).
| Adverse Event | Stage 1 - Cohort 1 (BTZ 250) | Stage 1 - Cohort 2 (BTZ 500) | Stage 1 - Cohort 3 (BTZ 750) | Stage 1 - Cohort 4 (BTZ 1000) | Stage 1 - Cohort 5 (BTZ 1250) | Stage 1 - Cohort 6 (BTZ 1500) | Stage 1 - Cohort 7 (BTZ 1750) | Stage 1 - Cohort 8 (BTZ 2000) | Stage 2 - Arm 1 (BTZ High) | Stage 2 - Arm 2 (BTZ Medium) | Stage 2 - Arm 3 (BTZ Low) | Stage 2 - Arm 4 (Control) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Safety and Tolerability of BTZ-043 | 3 | 17 | 3 | 4 | 15 | 10 | 14 | — | 35 | 17 | 21 | 9 |
Liquid culture is inoculated with overnight sputum of the participants. Upon growth of Mycobacteria, the color of the medium is changing due to changes in pH. This is measured photometric and the time of the change in color is recorded. The more bactera are inoculated, the quicker the change ind color and the time to positivity. Overnight sputum is collected on Day -1, Day 0, Day 2, Day 3, Day 4, Day 6, Day 8, Day 11 and Day 14 to be able to follow the decrease in bacterial load over time.
| log(10) TTP (hrs) day 14 ch.f.baseline | Stage 1 - Cohort 1 (BTZ 250) | Stage 1 - Cohort 2 (BTZ 500) | Stage 1 - Cohort 3 (BTZ 750) | Stage 1 - Cohort 4 (BTZ 1000) | Stage 1 - Cohort 5 (BTZ 1250) | Stage 1 - Cohort 6 (BTZ 1500) | Stage 1 - Cohort 7 (BTZ 1750) | Stage 1 - Cohort 8 (BTZ 2000) | Stage 2 - Arm 1 (BTZ High) | Stage 2 - Arm 2 (BTZ Medium) | Stage 2 - Arm 3 (BTZ Low) | Stage 2 - Arm 4 (Control) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bactericidal Activity Endpoint - MGIT Time to Positivity (log10 (h)) | 0.09 ± 0.10 | 0.22 ± 0.07 | 0.27 ± 0.17 | 0.24 | 0.18 ± 0.16 | 0.37 ± 0.16 | 0.25 ± 0.09 | — | 0.17 ± 0.12 | 0.25 ± 0.08 | 0.20 ± 0.14 | 0.42 ± 0.10 |
Overnight sputum was plated on solid medium. Decrease in log 10 CFU (No. of colony forming untis) over time was assessed. Overnight sputum is collected on Day -1, Day 0, Day 2, Day 3, Day 4, Day 6, Day 8, Day 11 and Day 14 to be able to follow the decrease in bacterial load over time.
| log(10)CFU/mL day 14 ch.f.baseline | Stage 1 - Cohort 1 (BTZ 250) | Stage 1 - Cohort 2 (BTZ 500) | Stage 1 - Cohort 3 (BTZ 750) | Stage 1 - Cohort 4 (BTZ 1000) | Stage 1 - Cohort 5 (BTZ 1250) | Stage 1 - Cohort 6 (BTZ 1500) | Stage 1 - Cohort 7 (BTZ 1750) | Stage 1 - Cohort 8 (BTZ 2000) | Stage 2 - Arm 1 (BTZ High) | Stage 2 - Arm 2 (BTZ Medium) | Stage 2 - Arm 3 (BTZ Low) | Stage 2 - Arm 4 (Control) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bactericidal Activity Endpoint - CFU | -0.42 ± 0.76 | -1.34 ± 0.27 | -1.29 ± 0.52 | -1.08 | -1.63 ± 0.63 | -2.22 ± 1.18 | -0.96 ± 1.24 | — | -2.09 ± 1.27 | -1.78 ± 0.85 | -1.48 ± 1.42 | -2.66 ± 0.91 |
Collected over From the beginning of screening (day -8) to the first administration of study drug (stage 1: Day 1) or probe drug administration (stage 2: Day 0), all symptoms etc. have been recorded as medical history. Adverse events were recorded from the first administration of study drug (stage 1) or probe drug (stage 2) until the follow-up visit on Day 22.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Stage 1 - Cohort 1 (BTZ 250) | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Stage 1 - Cohort 2 (BTZ 500) | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Stage 1 - Cohort 3 (BTZ 750) | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) |
| Stage 1 - Cohort 4 (BTZ 1000) | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| Stage 1 - Cohort 5 (BTZ 1250) | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Stage 1 - Cohort 6 (BTZ 1500) | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Stage 1 - Cohort 7 (BTZ 1750) | 0/6 (0%) | 1/6 (16.7%) | 6/6 (100%) |
| Stage 1 - Cohort 8 (BTZ 2000) | — | — | — |
| Stage 2 - Arm 1 (BTZ High) | 0/16 (0%) | 1/16 (6.3%) | 13/16 (81.3%) |
| Stage 2 - Arm 2 (BTZ Medium) | 1/14 (7.1%) | 1/14 (7.1%) | 10/14 (71.4%) |
| Stage 2 - Arm 3 (BTZ Low) | 0/15 (0%) | 1/15 (6.7%) | 11/15 (73.3%) |
| Stage 2 - Arm 4 (Control) | 0/9 (0%) | 0/9 (0%) | 6/9 (66.7%) |
| Event | Stage 1 - Cohort 1 (BTZ 250) | Stage 1 - Cohort 2 (BTZ 500) | Stage 1 - Cohort 3 (BTZ 750) | Stage 1 - Cohort 4 (BTZ 1000) | Stage 1 - Cohort 5 (BTZ 1250) | Stage 1 - Cohort 6 (BTZ 1500) | Stage 1 - Cohort 7 (BTZ 1750) | Stage 1 - Cohort 8 (BTZ 2000) | Stage 2 - Arm 1 (BTZ High) | Stage 2 - Arm 2 (BTZ Medium) | Stage 2 - Arm 3 (BTZ Low) | Stage 2 - Arm 4 (Control) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HaemoptysisRespiratory, thoracic and mediastinal disorders | — | — | — | — | — | — | 1/6 | — | 0/16 | 0/14 | 0/15 | — |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | — | — | — | — | — | — | 0/6 | — | 0/16 | 1/14 | 0/15 | 0/9 |
| Pulmonary tuberculosisInfections and infestations | — | — | — | — | — | — | 0/6 | — | 0/16 | 0/14 | 1/15 | — |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | — | — | — | — | — | — | 0/6 | — | 1/16 | 0/14 | 0/15 | 0/9 |
| Event | Stage 1 - Cohort 1 (BTZ 250) | Stage 1 - Cohort 2 (BTZ 500) | Stage 1 - Cohort 3 (BTZ 750) | Stage 1 - Cohort 4 (BTZ 1000) | Stage 1 - Cohort 5 (BTZ 1250) | Stage 1 - Cohort 6 (BTZ 1500) | Stage 1 - Cohort 7 (BTZ 1750) | Stage 1 - Cohort 8 (BTZ 2000) | Stage 2 - Arm 1 (BTZ High) | Stage 2 - Arm 2 (BTZ Medium) | Stage 2 - Arm 3 (BTZ Low) | Stage 2 - Arm 4 (Control) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 0/3 | 1/3 | 0/3 | 0/3 | 2/3 | 3/3 | 1/6 | — | 1/16 | 1/14 | 0/15 | 1/9 |
| Conjunctiva IrritationEye disorders | 2/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/6 | — | 1/16 | 0/14 | 1/15 | 1/9 |
| DizzinessNervous system disorders | 0/3 | 0/3 | 1/3 | 0/3 | 1/3 | 2/3 | 0/6 | — | 5/16 | 0/14 | 1/15 | 0/9 |
| Pleuritic painRespiratory, thoracic and mediastinal disorders | 0/3 | 2/3 | 0/3 | 0/3 | 1/3 | 0/3 | 0/6 | — | 0/16 | 0/14 | 0/15 | 0/9 |
| VomitingGastrointestinal disorders | 0/3 | 0/3 | 0/3 | 1/3 | 2/3 | 1/3 | 1/6 | — | 1/16 | 2/14 | 0/15 | 0/9 |
| HeadacheNervous system disorders | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/6 | — | 3/16 | 5/14 | 2/15 | 0/9 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 1/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 1/6 | — | 0/16 | 0/14 | 0/15 | 0/9 |
| Blood pressure increasedInvestigations | 0/3 | 0/3 | 1/3 | 0/3 | 0/3 | 0/3 | 0/6 | — | 0/16 | 0/14 | 0/15 | 0/9 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 0/3 | 1/3 | 1/3 | 0/3 | 0/3 | 0/3 | 2/6 | — | 1/16 | 1/14 | 1/15 | 0/9 |
| Herpes ZosterInfections and infestations | 0/3 | 0/3 | 0/3 | 1/3 | 0/3 | 0/3 | 0/6 | — | 0/16 | 0/14 | 0/15 | 0/9 |
The TSC decided based on the data not to enrol cohort 8.
| Age, Continuous(years) | Stage 1 - Cohort 1 (BTZ 250) | Stage 1 - Cohort 2 (BTZ 500) | Stage 1 - Cohort 3 (BTZ 750) | Stage 1 - Cohort 4 (BTZ 1000) | Stage 1 - Cohort 5 (BTZ 1250) | Stage 1 - Cohort 6 (BTZ 1500) | Stage 1 - Cohort 7 (BTZ 1750) | Stage 1 - Cohort 8 (BTZ 2000) | Stage 2 - Arm 1 (BTZ High) | Stage 2 - Arm 2 (BTZ Medium) | Stage 2 - Arm 3 (BTZ Low) | Stage 2 - Arm 4 (Control) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 25.7 ± 3.06 | 45.7 ± 16.3 | 36.7 ± 14.4 | 27.7 ± 12.4 | 27.7 ± 9.09 | 26.3 ± 8.39 | 28.2 ± 6.31 | — | 30.5 ± 11.5 | 31.7 ± 10.1 | 30.2 ± 11.3 | 27.2 ± 8.97 | 30.4 ± 10.6 |
| Sex: Female, Male(Participants) | Stage 1 - Cohort 1 (BTZ 250) | Stage 1 - Cohort 2 (BTZ 500) | Stage 1 - Cohort 3 (BTZ 750) | Stage 1 - Cohort 4 (BTZ 1000) | Stage 1 - Cohort 5 (BTZ 1250) | Stage 1 - Cohort 6 (BTZ 1500) | Stage 1 - Cohort 7 (BTZ 1750) | Stage 1 - Cohort 8 (BTZ 2000) | Stage 2 - Arm 1 (BTZ High) | Stage 2 - Arm 2 (BTZ Medium) | Stage 2 - Arm 3 (BTZ Low) | Stage 2 - Arm 4 (Control) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 3 | 5 | 1 | 0 | 12 |
| Male | 3 | 2 | 3 | 2 | 3 | 3 | 5 | 0 | 13 | 9 | 14 | 9 | 66 |
| Race/Ethnicity, Customized(Participants) | Stage 1 - Cohort 1 (BTZ 250) | Stage 1 - Cohort 2 (BTZ 500) | Stage 1 - Cohort 3 (BTZ 750) | Stage 1 - Cohort 4 (BTZ 1000) | Stage 1 - Cohort 5 (BTZ 1250) | Stage 1 - Cohort 6 (BTZ 1500) | Stage 1 - Cohort 7 (BTZ 1750) | Stage 1 - Cohort 8 (BTZ 2000) | Stage 2 - Arm 1 (BTZ High) | Stage 2 - Arm 2 (BTZ Medium) | Stage 2 - Arm 3 (BTZ Low) | Stage 2 - Arm 4 (Control) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Black | 3 | 1 | 3 | 2 | 0 | 1 | 5 | 0 | 10 | 9 | 10 | 7 | 51 |
| Other | 0 | 1 | 0 | 1 | 3 | 2 | 1 | 0 | 6 | 5 | 5 | 2 | 26 |
| White | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Not Hispanic or Latino | 3 | 3 | 3 | 3 | 3 | 3 | 6 | 0 | 16 | 14 | 15 | 9 | 78 |
| Region of Enrollment(participants) | Stage 1 - Cohort 1 (BTZ 250) | Stage 1 - Cohort 2 (BTZ 500) | Stage 1 - Cohort 3 (BTZ 750) | Stage 1 - Cohort 4 (BTZ 1000) | Stage 1 - Cohort 5 (BTZ 1250) | Stage 1 - Cohort 6 (BTZ 1500) | Stage 1 - Cohort 7 (BTZ 1750) | Stage 1 - Cohort 8 (BTZ 2000) | Stage 2 - Arm 1 (BTZ High) | Stage 2 - Arm 2 (BTZ Medium) | Stage 2 - Arm 3 (BTZ Low) | Stage 2 - Arm 4 (Control) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| South Africa | 3 | 3 | 3 | 3 | 3 | 3 | 6 | — | 16 | 14 | 15 | 9 | 78 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2019 to primary completion in Mar 2022, 27 months.
Results were first posted in Aug 2026, 4 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: BTZ-043
Michael Hoelscher